1.66
0.05 (3.11%)
| Penutupan Terdahulu | 1.61 |
| Buka | 1.56 |
| Jumlah Dagangan | 259,776 |
| Purata Dagangan (3B) | 1,109,368 |
| Modal Pasaran | 15,629,763 |
| Harga / Jualan (P/S) | 262.62 |
| Harga / Buku (P/B) | 3.36 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.850 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.50% |
| Nisbah Semasa (MRQ) | 9.43 |
| Aliran Tunai Operasi (OCF TTM) | -5.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.15 M |
| Pulangan Atas Aset (ROA TTM) | -108.61% |
| Pulangan Atas Ekuiti (ROE TTM) | -185.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | Bullfrog AI Holdings, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.25 |
|
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| % Dimiliki oleh Orang Dalam | 25.96% |
| % Dimiliki oleh Institusi | 3.03% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Apr 2025 | Pengumuman | Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23 |
| 11 Apr 2025 | Pengumuman | Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| 27 Feb 2025 | Pengumuman | BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |